US Drug Recall Register

FDA Drug Recalls

17,898 recalls, newest first

Class III · Low risk Ongoing

Pancreaze

Reason Failed Stability Specifications

Vivus, Inc. NDC 62541-401-10 D-0896-2023
Class II · Moderate risk Terminated

Tizanidine Tablets

Reason Failed Dissolution Specifications: this repackaged product was recalled by the manufacturer, Dr. Reddy's Laboratories, Inc., due to out of specification results for dissolution.

Amerisource Health Services LLC NDC 68084-645-01 D-0892-2023
Class II · Moderate risk Ongoing

Tizanidine Tablets USP

Reason Failed dissolution specification: Out of specification results observed in 24-month long term stability testing.

Dr Reddy's Laboratories Limited NDC 55111-180-10 D-0923-2023
Class II · Moderate risk Terminated

Tramadol Hydrochloride Tablets

Reason Packaging defect: blister packaging inadequately sealed.

The Harvard Drug Group NDC 0904-7179-61 D-0878-2023
Class II · Moderate risk Ongoing

Dry Eye Relief Lubricant Eye Drops

Reason CGMP Deviations: good manufacturing deficiencies related to a lack of documentation of the fill line.

K.C. Pharmaceuticals, Inc NDC 49035-280-02 D-0898-2023
Class II · Moderate risk Ongoing

Original Eye Drops

Reason CGMP Deviations: good manufacturing deficiencies related to a lack of documentation of the fill line.

K.C. Pharmaceuticals, Inc NDC 49348-037-29 D-0897-2023
Class III · Low risk Ongoing

Tranexamic Acid USP Tablets

Reason Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

Avkare LLC NDC 50268-772-13 D-0875-2023
Class II · Moderate risk Terminated

Endometrin

Reason cGMP deviations: potential for Microbial Contamination of Non-Sterile Products

Ferring Pharmaceuticals Inc NDC 55566-6500-03 D-0879-2023
Class III · Low risk Terminated

Lysteda

Reason Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

Amring Pharmaceuticals Inc NDC 69918-301-30 D-0871-2023
Class III · Low risk Terminated

Glycopyrrolate Injection

Reason Labeling: Label Mix-up

HF Acquisition Co LLC NDC 51662-1487-3 D-0870-2023
Class II · Moderate risk Terminated

StellaLife VEGA Oral Care Gel

Reason cGMP deviations

Homeocare Laboratories, Inc. NDC 69685-112-01 D-0890-2023
Class II · Moderate risk Terminated

StellaLife VEGA Oral Care Gel

Reason cGMP deviations

Homeocare Laboratories, Inc. NDC 69685-102-02 D-0889-2023
Class II · Moderate risk Terminated

StellaLife VEGA Oral Care Spray

Reason cGMP deviations

Homeocare Laboratories, Inc. NDC 69685-101-02 D-0888-2023
Class II · Moderate risk Terminated

StellaLife VEGA Oral Care Rinse

Reason cGMP deviations

Homeocare Laboratories, Inc. NDC 69685-113-16 D-0887-2023
Class II · Moderate risk Terminated

StellaLife VEGA Oral Care Rinse

Reason cGMP deviations

Homeocare Laboratories, Inc. NDC 69685-103-16 D-0886-2023
Class II · Moderate risk Terminated

SnoreStop Naso Spray Bulk

Reason cGMP deviations

Homeocare Laboratories, Inc. NDC 61152-199-99 D-0885-2023
Class II · Moderate risk Terminated

DoloEar Earache Drops

Reason cGMP deviations

Homeocare Laboratories, Inc. NDC 55758-001-15 D-0884-2023
Class II · Moderate risk Terminated

Arnica 7 Cream

Reason cGMP deviations

Homeocare Laboratories, Inc. D-0881-2023
Class I · High risk Terminated

ZIPRASIDONE HYDROCHLORIDE CAPSULES 20 mg

Reason Labeling: Label Mix-up: Unit Dose cartons labeled as Ziprasidone Hydrochloride Capsules, 20 mg were found to contain blister packages labeled as and containing Dronabinol Capsules, USP, 2.5 mg.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-6269-08 D-0893-2023
Class II · Moderate risk Terminated

Extended Phenytoin Sodium Capsules

Reason Failed Dissolution Specifications: Out-of-specification results for dissolution (above specification)

Amneal Pharmaceuticals of New York, LLC NDC 65162-212-10 D-0876-2023